Survival Analysis of Glioblastoma Multiforme
- PMID: 30256068
- PMCID: PMC6249474
- DOI: 10.22034/APJCP.2018.19.9.2613
Survival Analysis of Glioblastoma Multiforme
Abstract
Introduction: To evaluate the survival of Glioblastoma Multiforme (GBM). Material and Methods: Patients with a pathological diagnosis of Glioblastoma Multiforme (GBM) between 1 January 1994 and 30 November 2013, were retrospectively reviewed. Inclusion criteria: 1) GBM patients with confirmed pathology, 2) GBM patients were treated by multimodality therapy. Exclusion criteria: 1) GBM patients with unconfirmed pathology, 2) GBM patients with spinal involvement, 3) GBM patients with incomplete data records. Seventy-seven patients were treated by multimodality therapy such as surgery plus post-operative radiotherapy (PORT), post-operative Temozolomide (TMZ) concurrent with radiotherapy (CCRT), post-operative CCRT with adjuvant TMZ. The overall survival was calculated by the Kaplan-Meier method and the log-rank test was used to compare the survival curves. A p-value of ≤ 0.05 was considered to be statistically significant. Results: Seventy-seven patients with a median age of 53 years (range 4-76 years) showed a median survival time (MST) of 12 months. In subgroup analyses, the PORT patients revealed a MST of 11 months and 2 year overall survival (OS) rates were 17.2%, the patients with post-operative CCRT with or without adjuvant TMZ revealed a MST of 23 months and 2 year OS rates were 38.2%. The MST of patients by Recursive Partitioning Analysis (RPA), classifications III, IV, V, VI were 26.8 months, 14.2 months, 9.9 months, and 4.0 months, (p <0.001). Conclusions: The MST of the patients who had post-operative CCRT with or without adjuvant TMZ was better than the PORT group. The RPA classification can be used to predict survival. Multimodality therapy demonstrated the most effective treatment outcome. Temozolomide might be beneficial for GBM patients in order to increase survival time.
Keywords: Glioblastoma multiforme; post-operative radiotherapy; median survival time; survival rate.
Creative Commons Attribution License
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6249474/bin/APJCP-19-2613-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6249474/bin/APJCP-19-2613-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6249474/bin/APJCP-19-2613-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6249474/bin/APJCP-19-2613-g004.gif)
Similar articles
-
Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.Indian J Cancer. 2019 Jan-Mar;56(1):59-64. doi: 10.4103/ijc.IJC_128_18. Indian J Cancer. 2019. PMID: 30950447
-
Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.J Neurooncol. 2018 Sep;139(2):411-419. doi: 10.1007/s11060-018-2879-4. Epub 2018 Apr 25. J Neurooncol. 2018. PMID: 29696530
-
A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord.J Neurosurg Pediatr. 2017 Feb;19(2):239-248. doi: 10.3171/2016.8.PEDS1631. Epub 2016 Nov 4. J Neurosurg Pediatr. 2017. PMID: 27813458 Review.
-
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.World J Surg Oncol. 2016 Aug 24;14(1):225. doi: 10.1186/s12957-016-0975-5. World J Surg Oncol. 2016. PMID: 27557526 Free PMC article. Review.
-
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.J Neurooncol. 2015 Jun;123(2):251-7. doi: 10.1007/s11060-015-1791-4. Epub 2015 Apr 29. J Neurooncol. 2015. PMID: 25920710 Clinical Trial.
Cited by
-
SENP1-Mediated deSUMOylation Regulates the Tumor Remodeling of Glioma Stem Cells Under Hypoxic Stress.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241257490. doi: 10.1177/15330338241257490. Technol Cancer Res Treat. 2024. PMID: 38803001 Free PMC article.
-
Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy.Biomolecules. 2024 Apr 15;14(4):480. doi: 10.3390/biom14040480. Biomolecules. 2024. PMID: 38672496 Free PMC article. Review.
-
USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.CNS Neurosci Ther. 2024 Apr;30(4):e14711. doi: 10.1111/cns.14711. CNS Neurosci Ther. 2024. PMID: 38644551 Free PMC article.
-
A rare case of atypical intradural extramedullary glioblastoma diagnosed utilizing next-generation sequencing and methylation profiling: illustrative case.J Neurosurg Case Lessons. 2024 Apr 15;7(16):CASE24103. doi: 10.3171/CASE24103. Print 2024 Apr 15. J Neurosurg Case Lessons. 2024. PMID: 38621302 Free PMC article.
-
The effect of indicators of CALLY index on survival in glioblastoma.Ir J Med Sci. 2024 Apr 1. doi: 10.1007/s11845-024-03666-w. Online ahead of print. Ir J Med Sci. 2024. PMID: 38561591
References
-
- Ahmadloo N, Kani AA, Mohammadianpanah M, et al. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Cancer Inst. 2013;25:21–30. - PubMed
-
- Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma:A meta-analysis of clinical trials. J Cell Physiol. 2018;233:378–86. - PubMed
-
- Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–92. - PubMed
-
- Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–10. - PubMed